CClinicalTrials.gg
Sign In
CompletedNCT03871517Updated Jan 9, 2023

INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

A Phase 4 interventional study of Indobufen and Aspirin in Ischemic Stroke, Indobufen and Aspirin, sponsored by Beijing Tiantan Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-01-09.

Sponsored by Beijing Tiantan Hospital · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
5,438
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

China has the largest burden of cerebrovascular disease in the world. About 60% to 80% of which are ischemic stroke. In recent years, stroke has replaced heart disease and tumor diseases as the first cause of death and disability in adult population. The primary purpose of this study is to evaluate the efficacy of indobufen treatment in reducing the risk of a 3-month new stroke (any type of stroke, including ischemic stroke and hemorrhagic stroke) for patients with moderate/severe ischemic stroke is not inferior to aspirin therapy.

Read the detailed description

China has the largest burden of cerebrovascular disease in the world. About 60% to 80% of which are ischemic stroke. In recent years, stroke has replaced heart disease and tumor diseases as the first cause of death and disability in adult population. The primary purpose of this study is to evaluate the efficacy of indobufen treatment in reducing the risk of a 3-month new stroke (any type of stroke, including ischemic stroke and hemorrhagic stroke) for patients with moderate/severe ischemic stroke is not inferior to aspirin therapy. The study is a multicenter, randomized, double-blind, positive drug parallel control and non-inferiority clinical design.

Non-inferiority analysis was performed on the primary efficacy analysis, and both intent analysis (ITT) and compliance program set (PPS) were used for analysis. If the indobufen group was confirmed to be non-inferior to aspirin (control group), a superiority analysis was further performed to analyze whether the indobufen was superior to aspirin. At the same time, Kaplan-Meier curves were used to simulate the cumulative risk of stroke (ischemic or hemorrhagic) at 90-day follow-up, and the Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval, Log-rank test was used to evaluate the treatment effect. All statistics will be two-sided with p\<0.05 considered significant.

All patients who received study drugs and with at least one safety follow-up record will be included in the safety population. The data for safety evaluation included adverse reactions observed during the trial and changes in laboratory data before and after treatment.

02

Conditions studied

  • Ischemic Stroke
  • Indobufen
  • Aspirin
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's enrollment of 5,438 is above the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 465 studies on the registry; 282 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Female or male aged≥18 years and\<80years.
  • Acute moderate/severe ischemic stroke, 4≤NIHSS（National Institute of Health stroke scale）≤18 at the time of randomization.
  • Patients can be randomized within 72 hours of symptoms onset.
  • Provision of informed consent prior to any study specific procedures. * Symptom onset is defined by the "last seen normal" principle

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of intracerebral hemorrhage such as cerebral hemorrhage, subarachnoid hemorrhage, etc.
  • Diagnosis of hemorrhage or other pathology, such as vascular malformation, tumor, abscess or other major non-ischemic brain disease (e.g., multiple sclerosis) on baseline head CT or MRI.
  • Moderate to severe ischemic stroke induced by angioplasty/vascular surgery.
  • Modified Rankin Scale Score>2 at randomization (pre-morbid historical assessment).
  • History of aneurysm (including intracranial aneurysm or peripheral aneurysms).
  • Clear indication for anticoagulation (presumed cardiac source of embolus, e.g., atrial fibrillation, atrial myxoma, prosthetic cardiac valves known or suspected endocarditis).
  • History of Hemostatic disorder, systemic bleeding, thrombocytopenia or neutropenia.
  • History of previous symptomatic non-traumatic intracerebral bleed or cerebral artery amyloidosis.
  • Gastrointestinal (GI) bleed within the past 6 months before randomization.
  • Major surgery within the past 3 months before randomization.
  • Severe renal or hepatic insufficiency. (Severe hepatic insufficiency is defined as alanine aminotransferase (ALT) value>3 times normal upper limit or Aspartate aminotransferase (AST)>2 times normal upper limit; Severe renal insufficiency is defined as creatinine>2 times normal upper limit).
  • Diagnosis or of acute coronary syndrome.
  • Other antithrombotic therapy are required during the study, including antiplatelet therapy(such as open-labeled aspirin, GPIIb/IIIa inhibitors, clopidogrel, ticagrelor, prasugrel, dipyridamole, ozagrel, cilostazol, etc.) and anticoagulant therapy(such as warfarin, thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, heparin and low molecular heparin, etc.).
  • Within randomized 24 hours prior to any venous or arterial thrombolysis, mechanical bolt, snake venom, defibrase, lumbrokinase, etc.
  • Heparin or oral anticoagulants were used within 10 days of randomization.
  • Have a history of drug or food allergy and are known to be allergic to the study drug ingredients
  • Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months (if clinically indicated, vascular imaging should be performed prior to randomization whenever possible)
  • Anticipated requirement for long-term (>7 days) non-steroidal antiinflammatory drugs (NSAIDs).
  • The blood pressure needs to be controlled within the range of 90mmHg/60mmHg to 220mmHg/120mmHg.
  • Suffering from serious cardiopulmonary disease, the researchers believe that it is not suitable for this study
  • Patients with life expectancy\<3 months or patients who are unable to complete the study for other reasons.
  • Women of childbearing age who are negative in pregnancy test but refuse to practice reliable contraception. Women who are pregnant or lactating.
  • Involving in other investigational drug or device tests within the past 30 days before randomization.
  • Inability of the patient to understand and/or comply with study procedures and/or follow-up due to mental illness, cognitive or emotional disorders
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5,438 participants (actual)

Study arms

  • Experimental
    Indobufen

    Drug: Indobufen and aspirin mimetic Day 1 to 90±7: The first time : Indobufen 100mg + aspirin mimetic The second time: indobufen 100mg

    Drug: Indobufen

  • Active comparator
    Aspirin

    Drug: Aspirin and Indobufen mimetic Day 1 to 90±7: The first time : aspirin 100mg+ Indobufen mimetic, The second time: indobufen mimetic.

    Drug: Aspirin

Interventions

  • DrugIndobufen

    Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.

  • DrugAspirin

    Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.

06

What researchers measure

Primary outcomes

  1. Any new stroke event (ischemic stroke or hemorrhagic stroke)

    To evaluate the efficacy of indobufen treatment in reducing the risk of a 3-month new stroke (any type of stroke, including ischemic stroke and hemorrhagic stroke) for patients with moderate/severe ischemic stroke is not inferior to aspirin therapy.

    Time frame: 3 months after randomization

  2. Severe or moderate bleeding

    GUSTO definition

    Time frame: 3 months after randomization

Secondary outcomes

  1. Any new stroke event

    ischemic stroke or hemorrhagic stroke

    Time frame: 1 year after randomization

  2. New vascular events

    ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death

    Time frame: 1 year after randomization

  3. New ischemic stroke events

    New ischemic stroke events

    Time frame: within 3 months and 1 year after randomization

  4. modified Rankin Scale (mRS) score was compared between 0-2 and 3-6 in the two groups.

    The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It has become the most widely used clinical outcome measure for stroke clinical trials. The scale runs from 0-6, running from perfect health without symptoms to death: 0 - No symptoms.1 - No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead. The mRS scores between 3 to 6 points are considered to be poor functional outcome.

    Time frame: During the 3-month and 1-year follow-up

  5. The proportion of mRS scores between 3 to 6 points

    The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It has become the most widely used clinical outcome measure for stroke clinical trials. The scale runs from 0-6, running from perfect health without symptoms to death: 0 - No symptoms.1 - No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead. The mRS scores between 3 to 6 points are considered to be poor functional outcome.

    Time frame: 3 months and 1 year

  6. Changes in neurological impairment

    changes in National Institutes of Health Stroke Scale (NIHSS) score at 3 months compared to baseline. The NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0. Stroke severity: 0 No stroke symptoms;1-4 Minor stroke;5-15 Moderate stroke;16-20 Moderate to severe stroke;21-42 Severe stroke

    Time frame: 3 months after randomization

  7. Quality of life at 3 months and 1 year follow-up

    We will use the EQ-5D-5L scale to evaluate the quality of life. EQ-5D-5L is a standardized instrument for measuring generic health status. It has been widely used in population health surveys, clinical studies, economic evaluation and in routine outcome measurement in the delivery of operational healthcare. The EQ-5D-5L has five domain scales (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) and five levels for each domain.

    Time frame: 3 months and 1 year after randomization

  8. The proportion of early lower extremity venous thrombosis.

    The proportion of early lower extremity venous thrombosis.

    Time frame: 3 months after randomization

  9. All bleeding events

    all bleeding: including severe or moderate hemorrhage, intracranial hemorrhage

    Time frame: 3 months after randomization

  10. death

    death

    Time frame: 3 months after randomization

  11. Adverse events or serious adverse events

    such as gastrointestinal reaction, gastrointestinal bleeding and renal impairment

    Time frame: 3 months after randomization

07

Study locations

1 site
  • Beijing Tian Tan Hospital, Capital Medical University
    Beijing, Beijing 100050, China
08

References and documents

Publications

  • Pan Y, Meng X, Chen W, Jing J, Lin J, Jiang Y, Johnston SC, Bath PM, Dong Q, Xu AD, Li H, Wang Y. Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. Stroke Vasc Neurol. 2022 Oct;7(5):457-461. doi: 10.1136/svn-2021-001480. Epub 2022 Apr 7. Erratum In: Stroke Vasc Neurol. 2023 Aug;8(4):e2. doi: 10.1136/svn-2021-001480corr1. PubMed 35393360 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03871517
Lead sponsor
Beijing Tiantan Hospital
Responsible party
Yongjun Wang (Executive Vice-President, Beijing Tiantan Hospital) — Principal investigator
First posted
Mar 12, 2019
Start date
Jun 3, 2019
Primary completion
Mar 1, 2022
Completion
Dec 1, 2022
Last update
Jan 9, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Stroke→

Other studies from this sponsor

Beijing Tiantan Hospital

Start the discussion